Page Menu

Michael R Green

Inventions:

Title: Identification of Epigenetic Modifiers of the Silenced FMR1 Gene: Potential Targets for Fragile X Syndrome Therapeutics. UMMS16-03; Patent Pending.

This invention comprises methods for treating Fragile X Syndrome and other FMR1-inactivation-associated disorders by inhibiting epigenetic silencers of the FMR1 gene. The invention discloses a variety of FMR1 modulators, functioning either through RNA interference or small molecule inhibition, for optimal FMR1 reactivation. more info.
- Technology: RNAi/micro-RNA Therapy, Small Molecules
- Applications: Fragile X syndrome/Fragile X-associated tremor/ataxia syndrome, Polycystic ovarian syndrome, Premature ovarian aging

Title: New XCI Inhibitors as Potential Rett Syndrome Therapeutics. UMMS15-53; Patent Pending.

This invention provides methods of treating a subject having a dominant X-linked disease, the method comprising administering to the subject an X chromosome inactivation factor (XCIF) inhibitor in an amount effective for inducing expression a target X-linked gene. The invention provides small molecule and oligonucleotide XCIF inhibitors. In some embodiments, the X-linked gene is MECP2 and the X-linked disease is Rett Syndrome. more info.
- Technology: RNAi/micro-RNA Therapy, Small Molecules
- Applications: Rett Syndrome, Hypophosphatemia, Incontinentia pigmenti, Aicardi, CHILD syndrome, Dermal hypoplasia, Lujan-Fryns syndrome, Nephritis, Fragile X syndrome/Fragile X-associated tremor/ataxia syndrome, Charcot-Marie-Tooth disease, Myopathy, Dysplasia

Title: A Method to Treat Chronic Myelogenous Leukemia (CML) Patients who have Developed BCR-ABL-Independent Imatinib Resistance and to Eradicate CML Stem Cells. UMMS14-47; Patent Pending.

This new innovation addresses the issues associated drug resistance of chronic myeloid leukiemia (CML) cells to imatinib mesylate (IM). IM improves patient survival and are used widely to treat early stages of CML, but the efficacy is known to drop when drug resistance is developed. This new invention builds on the finding that in IM resistant CML cells, RAF/MEK/ERK pathway is activated that is not subjected to IM targeting. Remarkably, when FDA approved MEK inhibitor, trametinib is treated in conjunction with IM, they synergistically kill CML cells and improve survival in mouse models. more info.
- Technoloy: Small Molecules
- Applications: Cancer, Chronic myeloid leukiemia (CML)

Title: SRPX FOR TREATMENT OF CANCER. UMMS 12-08; Patent 9,290,744

This technology provides compositions and methods of treatment for lung cancer. The invention is based on a discovery the tumor suppressor, SRPX is found at low levels of expression in solid human tumors compared to normal tissue. When SRPX is introduced at sufficient levels to tumor cells, SRPX can induce apoptosis and senescence to inhibit cellular proliferation. SRPX can easily be administered using the AAV gene therapy method and markedly suppresses lung cancer in mice. more info.
- Technology: Gene Therapy, Biologics
- Indications: AAV, Cancer, Lung cancer
- Patent Expiration Dates: 2032-09-14

Title: Identification of Genes Preferentially Required for Growth of p53-Deficient Human Cancer Cells. UMMS09-56; Patent Pending.

This invention discloses a novel cluster of genes discovered through a RNAi screen which could be a potential target of cancer treatment in p53 mutation cancers. p53 gene is mutated in numerous cancer therefore the newly discovered genes have potential for becoming a therapeutic target in wide range of cancers. The inventors performed a bias screen using p53 mutant cancer cells, p53-/- and +/- colorectal HCT116 cell lines and shRNA library. This screening yielded a selection of genes that are preferentially required for viability in p53 mutant cancer cells. The verification experiments showed that a 24 gene-knockdown preferentially impaired growth of the p53 cell line. Using mice xenograft, 4 required genes were identified and show high potential for clinical use.
- Technology: RNAi/micro-RNA Therapy, Small Molecules
- Applications: p53 mutant cancer, Cancer

Innovation Topics: RNAi/micro-RNA Therapy, Small Molecules, Fragile X syndrome/Fragile X-associated tremor/ataxia syndrome, Polycystic ovarian syndrome, Premature ovarian aging, Rett Syndrome, Hypophosphatemia, Incontinentia pigmenti, Aicardi, CHILD syndrome, Dermal hypoplasia, Lujan-Fryns syndrome, Nephritis, Fragile X syndrome/Fragile X-associated tremor/ataxia syndrome, Charcot-Marie-Tooth disease, Myopathy, Dysplasia, Cancer, Chronic myeloid leukiemia (CML), Gene Therapy, Biologics, AAV, Lung cancer, p53 mutant cancer